Latest News by Industry
DUBLIN--(BUSINESS WIRE)--Sep 26, 2022--
The "Global Pernicious Anemia Market Research and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.
The global pernicious anemia diagnosis and treatment market is anticipated to grow at a significant CAGR of 7.1% during the forecast period. Pernicious anemia is a disease in which the formation of red blood cells becomes slow due to deficiency of vitamin B-12 in the human body. The prime cause behind the disease is an autoimmune disorder in which the antibody released by the immune system harms the intrinsic factor present in the stomach.
The intrinsic factors play a vital role in the absorption of vitamin B-12 from the food. The deficiency of B-12 leads to a shortage of red blood cells in the bloodstream thereby leading to carry less oxygen to the blood. Elderly people are more prone to such diseases. The increasing prevalence of autoimmune conditions or intestinal diseases is the major motivating factor for the growth of the global pernicious anemia market. Moreover, effective medication techniques for treating autoimmune disorders also account for the growth of the market.
The lack of awareness about the treatment of disease and the high cost of the drug is the major factors restraining the growth of the market. The supportive government regulations and increased expenditure for the development of healthcare infrastructure will create more room for future growth of the market. Moreover, the rapid research and development in the field of novel treatment methods will also help in increasing the market across the globe.
Market Players Outlook
The competition in the global pernicious anemia diagnosis and treatment market is moderate as the companies present in the market are not so active. The market players are engaged in providing various B-12 vitamin injections, sprays, immunosuppressant drugs, and tests for Intrinsic factor deficiency. The key players in the pernicious anemia market include American Regent, Inc., Daiichi Sankyo Co, Ltd., Emisphere Technologies, Inc, and so on. The companies are engaged in rapid research and development for the development of effective treatment measures for the disease.
The Report Covers
Key Topics Covered:
1. Report Summary
2. Market Overview and Insights
3. Competitive Landscape
4. Market Determinants
5. Market Segmentation
6. Regional Analysis
7. Company Profiles
Companies Mentioned
For more information about this report visit https://www.researchandmarkets.com/r/qe048j
View source version on businesswire.com:https://www.businesswire.com/news/home/20220926005289/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: PHARMACEUTICAL HEALTH CARDIOLOGY
SOURCE: Research and Markets
Copyright Business Wire 2022.
PUB: 09/26/2022 04:15 AM/DISC: 09/26/2022 04:17 AM
http://www.businesswire.com/news/home/20220926005289/en